Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 18/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19001459 | 0.91 | APLNR (0.52) | APLNR | |
| SCHEMBL19001460 | 0.89 | APLNR (0.40) | APLNR | |
| SCHEMBL19001439 | 0.88 | APLNR (0.53) | APLNRNPC1RAB9A | |
| SCHEMBL19001438 | 0.85 | APLNR (0.39) | APLNR | |
| SCHEMBL19001448 | 0.85 | APLNR (0.41) | APLNR | |
| SCHEMBL19001458 | 0.84 | APLNR (0.49) | APLNRSMN1; SMN2 | |
| SCHEMBL20584624 | 0.84 | APLNR (0.50) | APLNRKMT2A | |
| SCHEMBL20584793 | 0.84 | APLNR (0.38) | APLNR | |
| SCHEMBL28644394 | 0.83 | APLNR (0.39) | APLNR | |
| SCHEMBL20584407 | 0.83 | APLNR (0.53) | APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3390400-B1 | HETEROARYLHYDROXYPYRIMIDINONES AS AGONISTS OF THE APJ RECEPTOR | BRISTOL MYERS SQUIBB CO (US) | 2021-01-20 | — | — | EP | disclosed |
| US-10669261-B2 | Heteroarylhydroxypyrimidinones as agonists of the APJ receptor | Bristl-Myers Squibb Company (US) | 2020-06-02 | — | — | US | disclosed |
| US-20180362508-A1 | HETEROARYLHYDROXYPYRIMIDINONES AS AGONISTS OF THE APJ RECEPTOR | BRISTOL MYERS SQUIBB CO (US) | 2018-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669261-B2 | Heteroarylhydroxypyrimidinones as agonists of the APJ receptor | APLNR, GPBAR1, AGTR1 | APLNR 1/4885MEN1 4713/4885NPC1 1648/4885 |
| US-20180362508-A1 | HETEROARYLHYDROXYPYRIMIDINONES AS AGONISTS OF THE APJ RECEPTOR | APLNR, GPBAR1, AGTR1 | APLNR 1/4885MEN1 4713/4885NPC1 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.